The Impact of Antipsychotic Dose Reduction Within a Medicare Population
Objective: To analyze the burden of antipsychotic (AP) dose reduction in Medicare patients with schizophrenia (SZ). Background: Tardive dyskinesia (TD) develops in patients treated with…Deutetrabenazine Reduces Involuntary Movements in Patients Most Severely Impacted by Tardive Dyskinesia in a 3-year Open-Label Extension Trial
Objective: To evaluate the efficacy of deutetrabenazine (DTBZ) in reducing TD in the most severely impacted patients using data from an ongoing open-label extension (OLE)…Long-Term Treatment With Deutetrabenazine (DTBZ) Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From the Completed, 3-year Open-Label Extension (OLE) Study
Objective: To evaluate long-term efficacy and safety of DTBZ in patients with TD by examining change from baseline in Abnormal Involuntary Movement Scale (AIMS) scores…Long-term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia
Objective: To assess the long-term safety and efficacy of deutetrabenazine in younger (<55 years) and older (≥55 years) patients with tardive dyskinesia (TD). Background: TD…An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia
Objective: Evaluate the impact of orofacial tardive dyskinesia (TD) symptoms on the professional and social lives of patients with TD. Background: TD, a movement disorder…Clinically Relevant Changes in AIMS Based on Clinical and Patient Global Impression of Change in Patients With Tardive Dyskinesia Treated with Deutetrabenazine
Objective: To assess clinically relevant reductions with treatment of deutetrabenazine in abnormal involuntary movements in patients with tardive dyskinesia (TD), as evidenced by correlation between…Long-Term Outcomes in Patients with Tardive Dyskinesia who Were Early Responders with Valbenazine
Objective: To assess the long-term outcomes of once-daily valbenazine (VBZ) on tardive dyskinesia (TD) using a formal assessment (Abnormal Involuntary Movement Scale [AIMS]) in participants…Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia: Results From an Open-Label Extension Study
Objective: To evaluate long-term efficacy of deutetrabenazine in patients with tardive dyskinesia (TD) by examining the change from baseline in Abnormal Involuntary Movement Scale (AIMS)…Patient-centered approach to elicit and compare the treatment goals of patients with tardive dyskinesia, their care partners, and healthcare providers
Objective: To elicit and compare the treatment goals of patients with tardive dyskinesia (TD), their care partners, and healthcare providers (HCP). Background: Tardive dyskinesia (TD)…Long-Term Outcomes with Valbenazine 40 mg/day in Adults with Tardive Dyskinesia
Objective: To examine long-term outcomes in adults with tardive dyskinesia (TD) who received once-daily valbenazine (VBZ) 40 mg or had a dose reduction from 80…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 9
- Next Page »